

Nanabis™: A Non-Opioid Alternative for Management of Cancer Bone Pain

Authors : Sean Hall

Abstract : Prior to COVID-19, the world was preoccupied with opioids, effectiveness versus risk, and specifically toxicity versus abuse. Historically underpinning opioid use was a concept of safety. As use over time and real-world data evolved, a pursuit for efficacy associated with non-opioid alternatives became mainstream. On January 8, 2021, the US signed back into the opioid problem, with these two fundamental questions still unresolved. The author will share the current progression of a lead non-opioid cancer bone pain candidate, NanaBis™. NanaBis™ represents two innovative factors: The active ingredients are from cannabinoids; these ingredients are in a proprietary sub-micron delivery platform, NanoCelle®. The author will offer an opinion piece, potentiating the future role of delivery platforms in medicine to increase both patient safety and compliance.

Keywords : NanaBis, nanoCelle, opioids, toxicity

Conference Title : ICPMPM 2022 : International Conference on Cancer Pain Management and Pain Medicine

Conference Location : London, United Kingdom

Conference Dates : November 18-19, 2022